NICE has issued final guidance to the NHS recommending imatinib mesylate, also known as Glivec and made by Novartis, for up to 3 years for people who have had a gastro-intestinal stromal tumour (GIST) removed and who are at high risk of the cancer recurring.

GISTs are found in the digestive system, most commonly in the stomach and small bowel. Some are benign and cause few symptoms. If they become cancerous and are confined to one area, they can often be removed surgically.

Commenting on the guidance, Professor Carole Longson, health technology evaluation centre director at NICE, said: “Since the publication of the original guidance, clear evidence has emerged showing that giving imatinib after surgery can delay the recurrence of GISTs and in some cases increase survival. This updated guidance means that the NHS will provide imatinib for these patients.”

For more details, go to: https://www.nice.org.uk/news/press-and-media/nice-updated-guidance-recommends-imatinib-for-digestive-system-cancers